Category: AtriCure Inc.Syndicate content

AtriCure launches CryoIce treatment for pain

March 23, 2015 by Mark Hollmer

AtriCure launches its CryoIce ablation device for a new indication: Temporary pain relief for cardiac and thoracic surgery patients.

AtriCure launches CryoIce pain treatment

Ohio's AtriCure (NSDQ:ATRC) is promoting 1 of its cryoablation devices for a new indication, temporary pain relief for some cardiac surgery patients.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Ex-Insulet CFO Roberts lands at Avedro | Personnel Moves

January 23, 2015 by Brad Perriello

Avedro taps ex-Insulet CFO Brian Roberts to be its new finance chief, replacing Rhonda Bracey, who is relocating to the West Coast.

Ex-Insulet CFO Roberts lands at Avedro | Personnel Moves

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

FDA OKs new AtriCure afib trial

November 3, 2014 by Brad Perriello

The FDA grants an investigational device exemption for an AtriCure study of patients with non-paroxysmal atrial fibrillation.

FDA OKs new AtriCure afib trial

AtriCure (NSDQ:ATRC) said it won an investigational device exemption from the FDA for a 1st-of-its-kind clinical trial involving patients with non-paroxysmal atrial fibrillation.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

AtriCure renews outlook on another strong quarter

July 25, 2014 by Arezu Sarvestani

AtriCure gets some Wall Street love after again boosting its full-year expectations on the back of a 30% boost in revenues in its 2nd quarter.

AtriCure renews outlook on another strong quarter

Ohio-based AtriCure (NSDQ:ATRC) gained a few points today as investors reacted to new of the company's Q2 financial report.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

AtriCure tops Q1 sales estimates, raises 2014 outlook

April 28, 2014 by Brad Perriello

AtriCure's 1st-quarter sales rise 28% and beat expectations on Wall Street, prompting it to boost its revenue guidance for the rest of the year.

AtriCure tops Q1 sales estimates, raises 2014 outlook

AtriCure (NSDQ:ATRC) boosted its 1st quarter sales above Wall Street's forecast, posting nearly 28% growth, and raised its outlook on revenues for the rest of the year.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

AtriCure's Q4 prelims send shares up

January 10, 2014 by Brad Perriello

AtriCure's report of strong sales growth for the 4th quarter and 2013 sends share prices up on Wall Street.

AtriCure's Q4 prelims send shares up

Fresh off of the $34 million acquisition of Estech, AtriCure (NSDQ:ATRC) reported strong sales growth for the 4th quarter and 2013 and predicted even better gains for this year, sending share prices up today on Wall Street.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.